HomeCancerProstate

Prostate

A pathway to personalised therapy in prostate most cancers

Prostate most cancers (PC) stands because the second main reason for...

Karmanos, McLaren, Detroit Tigers Strike Out Prostate Most cancers

Revealed on: July 2, 2024 Particular occasion at Comerica Park promotes prostate well being and most cancers consciousness, celebrates prostate most cancers survivors...

FDA grants quick observe designation to 225Ac-FL-020 in mCRPC

The FDA has awarded a quick observe designation to 225Ac-FL-020, an investigational PSMA-targeting radionuclide drug conjugate for the potential remedy of sufferers with...

Assessing the Advantage of CAR T-cell Therapies for mCRPC

A primary-in-human section 1 trial (NCT03873805) investigated the security and bioactivity of prostate stem cell antigen-directed CAR T cells for sufferers with metastatic...

Dr Choudhury on Potential Future Trials Evaluating Therapy Interruption in mHSPC

Atish D. Choudhury, MD, PhD, senior doctor, chair, Gelb Heart for Translational Analysis, Dana-Farber Most cancers Heart, assistant professor of medication, Harvard Medical...

Hot Topics